Dr. Dorothy H. Bray to Chair Scientific Advisory Board at CytoDyn.SANTA FE, N.M. -- Dorothy H. Bray, Ph.D., will chair the Scientific Advisory Board at CytoDyn, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYDY), the Company announced today. Dr. Bray has garnered extensive experience in the development of drugs for HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome while serving in various senior positions at GlaxoSmithKline (NYSE NYSE See: New York Stock Exchange :GSK) and its predecessors, a leading provider of antiretroviral drugs. Dr. Bray previously led an industry-driven international program of several hundred international studies of HIV/AIDS therapy, including over a hundred conducted in developing countries. She has been involved in multiple international research programs including the DART trial, the largest HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. therapy trial ever conducted in Africa, the CIPRA projects funded by the U.S. National Institutes of Health, as well as advising on multiple clinical development programs in the biotech industry. Dr. Bray received her Ph.D. from the School of Pharmacy at the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies in 1988, and her Master of Science in Biology at the Jagiellonian University of Cracow, Poland, in 1979. Her awards and scholarships include The Winston Churchill Traveling Fellowship to study medicinal plants in Africa, The Sir Halley Stewart Trust Fellowship to study natural medicinal products, and The Royal Society Scholarship to study immunology in Paris. She serves as a reviewer for a number of scientific journals. CytoDyn is developing Cytolin[R], targeted immune therapy for HIV/AIDS that is designed to restore immune function and that has produced encouraging data in pilot clinical trials. "We believe Dr. Bray's experience and expertise will be valuable across our entire pipeline," said CytoDyn's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Allen D. Allen. The Company's pipeline includes a polyvalent polyvalent /poly·va·lent/ (-va´lent) multivalent. pol·y·va·lent adj. 1. Acting against or interacting with more than one kind of antigen, antibody, toxin, or microorganism. 2. family of DNA-based pre-vaccines for influenza, and a product, Formaxycin[TM], that is intended to treat pre-cancerous conditions of the skin based upon a natural product long used by traditional healers in Africa. Disclaimer The information about Dr. Bray contained in this release was provided by Dr. Bray and is relied on by the Company in good faith. Although Dr. Bray's credentials in the field of HIV/AIDS are well known among experts in that field, the Company has made no independent effort to confirm this information. There can be no assurance that the efforts of Dr. Bray on behalf of the Company, if any, will produce positive results for the Company or increase its value. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion